Advertisement

Diabetologia

, Volume 61, Issue 11, pp 2447–2457 | Cite as

Activation of insulin receptors and IGF-1 receptors in COLO-205 colon cancer xenografts by insulin and insulin analogue X10 does not enhance growth under normo- or hypoglycaemic conditions

  • Henning Hvid
  • Mikkel S. Jørgensen
  • Niels Blume
  • Rita Slaaby
  • Anne Lützen
  • Bo F. Hansen
Article

Abstract

Aims/hypothesis

Recent studies with normal rats and mouse allograft models have reported that insulin and insulin analogues do not activate the IGF-1 receptor in vivo, and that this characteristic therefore cannot be responsible for the increased incidence of mammary tumours observed for the insulin analogue X10 in chronic toxicity studies with Sprague Dawley rats. This is in clear contrast to reports of insulin and insulin analogues in vitro. Clarification of this is important for understanding the mechanisms behind possible growth-promoting effects of insulin analogues, and will have implications for the development of novel insulin analogues.

Methods

We established a xenograft model in BALB/c nude mice with the human colon cancer cell line COLO-205, which expresses human insulin and IGF-1 receptors, and explored the acute and chronic effects of treatment with supra-pharmacological doses of human insulin, insulin analogue X10 and human IGF-1. With a novel antibody, acute IGF-1 receptor activation was also examined in various tissues from normal rats treated with human insulin, insulin analogue X10 or human IGF-1. Finally, the effects of pharmacologically relevant doses of human insulin and insulin analogue X10 on receptor activation and growth of COLO-205 xenograft were explored in BALB/c nude mice with alloxan-induced hyperglycaemia.

Results

In normal rats and in BALB/c nude mice bearing a COLO-205 cell xenograft, treatment with supra-pharmacological doses of human insulin, insulin analogue X10 or human IGF-1 resulted in activation of insulin receptors as well as IGF-1 receptors. Treatment of diabetic nude mice with pharmacologically relevant doses of human insulin or insulin analogue X10, which decreased blood glucose from hyperglycaemic levels to the normoglycaemic range, did not increase IGF-1 receptor activation. Furthermore, repeated treatment with supra-pharmacological as well as pharmacological doses of human insulin or insulin analogue X10 did not influence the growth of COLO-205 xenografts.

Conclusions/interpretation

This study demonstrates that activation of IGF-1 receptors in cancer cells by insulin and insulin analogues cannot be considered as a purely in vitro phenomenon. It does occur in vivo in animal models, although only after treatment with supra-pharmacological doses. Furthermore, treatment with insulin or insulin analogue X10 did not influence the growth of COLO-205 xenografts under normo- or hypoglycaemic conditions. Further studies are needed before a conclusion can be reached on whether IGF-1 receptor activation by insulin analogues correlates with increased growth in vivo.

Keywords

IGF-1 IGF-1 receptor activation Insulin Insulin analogues Insulin receptor activation 

Abbreviation

IGF-1R

IGF-1 receptor

Notes

Acknowledgements

We thank A. Bowman, S. L. Riisberg and K. S. Tornqvist for technical assistance with the animal experiments, and P. Jensen, M. Stendal and C. H. Dahl for performing ELISAs for insulin receptor, IGF-1R and Akt activation (all at Insulin Research, Novo Nordisk, Maaloev, Denmark).

Contribution statement

This study was conceived and designed by HH, MSJ, NB, RS, AL, BFH. Acquisition of data was performed by HH, MSJ, NB, AL and BFH. Data were analysed and interpreted by HH, MSJ, NB, RS, AL and BFH. The manuscript was drafted and revised by HH, MSJ, NB, RS, AL and BFH. All authors gave final approval of the version to be published. HH is the guarantor of this work.

Funding

This study was funded entirely by Novo Nordisk. Representatives from Novo Nordisk other than the authors provided editorial assistance only.

Duality of interest

All authors are employees at Novo Nordisk and own shares in the company.

Supplementary material

125_2018_4684_MOESM1_ESM.pdf (436 kb)
ESM (PDF 436 kb)

References

  1. 1.
    Drejer K (1992) The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8:259–285CrossRefGoogle Scholar
  2. 2.
    Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732–1744CrossRefGoogle Scholar
  3. 3.
    Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52:1745–1754CrossRefGoogle Scholar
  4. 4.
    Investigators OT, Gerstein HC, Bosch J et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328CrossRefGoogle Scholar
  5. 5.
    Adami HO, McLaughlin J, Ekbom A et al (1991) Cancer risk in patients with diabetes mellitus. Cancer Causes Control 2:307–314CrossRefGoogle Scholar
  6. 6.
    Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160–1167CrossRefGoogle Scholar
  7. 7.
    Gallagher EJ, LeRoith D (2015) Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev 95:727–748CrossRefGoogle Scholar
  8. 8.
    Hansen BF, Danielsen GM, Drejer K et al (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315:271–279CrossRefGoogle Scholar
  9. 9.
    Kurtzhals P, Schaffer L, Sorensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005CrossRefGoogle Scholar
  10. 10.
    Slieker LJ, Brooke GS, DiMarchi RD et al (1997) Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 40(Suppl 2):S54–S61CrossRefGoogle Scholar
  11. 11.
    Hansen BF, Glendorf T, Hegelund AC et al (2012) Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10. PLoS One 7:e34274CrossRefGoogle Scholar
  12. 12.
    Gallagher EJ, Alikhani N, Tobin-Hess A et al (2013) Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor. Diabetes 62:3553–3560CrossRefGoogle Scholar
  13. 13.
    Gallagher EJ, Zelenko Z, Tobin-Hess A, Werner U, Tennagels N, LeRoith D (2016) Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes. Diabetologia 59:2018–2025CrossRefGoogle Scholar
  14. 14.
    Tennagels N, Welte S, Hofmann M, Brenk P, Schmidt R, Werner U (2013) Differences in metabolic and mitogenic signallingof insulin glargine and AspB10 human insulin in rats [corrected]. Diabetologia 56:1826–1834CrossRefGoogle Scholar
  15. 15.
    Werner U, Korn M, Schmidt R, Wendrich TM, Tennagels N (2014) Metabolic effect and receptor signalling profile of a non-metabolisable insulin glargine analogue. Arch Physiol Biochem 120:158–165CrossRefGoogle Scholar
  16. 16.
    Lundby A, Bolvig P, Hegelund AC et al (2015) Surface-expressed insulin receptors as well as IGF-I receptors both contribute to the mitogenic effects of human insulin and its analogues. J Appl Toxicol 35:842–850CrossRefGoogle Scholar
  17. 17.
    Committee for the Update of the Guide for the Care and Use of Laboratory Animals (2011) Guide for the Care and Use of Laboratory Animals. The National Academies Press, Washington DCGoogle Scholar
  18. 18.
    Hvid H, Blouin MJ, Birman E et al (2013) Treatment with insulin analog X10 and I GF-1 increases growth of colon cancer allografts. PLoS One 8:e79710CrossRefGoogle Scholar
  19. 19.
    Keene ON (1995) The log transformation is special. Stat Med 14:811–819CrossRefGoogle Scholar
  20. 20.
    Baricevic I, Jones DR, Roberts DL et al (2015) A framework for the in vitro evaluation of cancer-relevant molecular characteristics and mitogenic potency of insulin analogues. Carcinogenesis 36:1040–1050CrossRefGoogle Scholar
  21. 21.
    Clemmons D, Maile L, Xi G, Shen X, Radhakrishnan Y (2011) Igf-I signaling in response to hyperglycemia and the development of diabetic complications. Curr Diabetes Rev 7:235–245CrossRefGoogle Scholar
  22. 22.
    Bianchini F, Kaaks R, Vainio H (2002) Overweight, obesity, and cancer risk. Lancet Oncol 3:565–574CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Insulin ResearchNovo Nordisk A/SMaaloevDenmark

Personalised recommendations